Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2026 13:20 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Awarded $8M in Non-Dilutive Grant Funding from the California Institute for Regenerative Medicine (CIRM) to Support Clinical Development of SRN-101 in High-Grade Glioma

Siren Biotechnology awarded $8M in grant funding from the California Institute for Regenerative Medicine (CIRM) to support clinical development of SRN-101
June 25, 2026 11:39 ET | Source: 24/7 Market News

The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution

Cancer treatment is undergoing one of the most significant transformations in modern medical history.
June 24, 2026 19:31 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

REDWOOD CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today...
June 24, 2026 08:29 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

OCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted the significant progress achieved across its pancreatic cancer...
June 24, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit

SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
June 23, 2026 09:00 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
June 23, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic...
June 22, 2026 08:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series

OCALA, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will present in the Webull Corporate Connect Webinar Series...
June 22, 2026 08:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.

Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution...
June 22, 2026 07:00 ET | Source: CureWise, Inc

CureWise Founder and CEO Steve Brown to Speak at Aspen Ideas: Health 2026 and Launch AI-Powered Precision Oncology Platform

Steve Brown, founder and CEO of CureWise, will speak at Aspen Ideas: Health 2026, where he will launch the company’s AI-powered precision oncology platform